Introduction
Jaundice is the yellowish pigmentation of the skin, sclera and mucous membranes. 1 The yellow colour results from the accumulation of bilirubin pigment in the skin. 2 Neonatal jaundice or neonatal hyperbilirubinaemia refers to jaundice that is present at birth or appears at any time during the neonatal period. 2 In neonates, hyperbilirubinaemia is detected when the serum bilirubin levels become greater than 5 mg/dL and is termed clinical jaundice. 3 Jaundice can be physiological or pathological. 4 Physiological jaundice is a common problem in term and preterm infants during the first week after birth and is the result of increased bilirubin production from the breakdown of foetal red blood cells combined with transient limitations in the conjugation of bilirubin by the immature neonatal liver. 2 For most of these infants, jaundice is mild and resolves without treatment. More than 50% of normal newborn, and 80% of preterm infants, have some jaundice. 5 A small group of infants develop pathological jaundice. This may be an exaggeration of normal physiologic processes or may be an indicator of underlying disorders. 6 Pathological jaundice usually appears in the first 24 hours or after the first week of life, and the list of differential diagnoses include haemorrhage, sepsis, and congenital infections, such as toxoplasmosis, rubella, cytomegalovirus, herpes, and syphilis. 2 Risk factors of neonatal jaundice include low birth weight, prematurity, ABO incompatibility, and sepsis. 3 In Malawi, 10% of neonates are born to HIV seroreactive mothers. 9 Several studies have found very high rates of prematurity, low birth weight, and very low birth weight (all risk factors for neonatal jaundice) in the infants of HIVpositive mothers. 8, 9 In addition, other perinatal infections that predispose neonates to jaundice, such as hepatitis B and C, syphilis, toxoplasmosis, cytomegalovirus, herpes simplex virus, and tuberculosis exhibit high co-morbidity with HIV. 10 Nevirapine has been known to cause hepatic inflammation and therefore is associated with increased levels of serum bilirubin. 10, 11 The new prevention of motherto-child transmission (PMTCT) guidelines from single-dose nevirapine prophylaxis to a six-week course in newborns, 10 means that, in theory, the risk of developing clinical jaundice in HIV-exposed neonates is increased. Non-invasive techniques for bilirubin measurement that correlate with serum bilirubin levels, such as with the use of a transcutaneous bilirubinometer, may be used to screen infants, but determination of serum bilirubin level is indicated in patients with elevated age-specific transcutaneous measurement, progressing jaundice, or risk for either haemolysis or sepsis. 2 Severe jaundice is defined as clinical jaundice and serum bilirubin levels above treatment threshold levels for gestational age and postpartum age. If the bilirubin level is greater than the threshold value, the neonate is started on phototherapy. 12 The levels of bilirubin, which are determined as supra-threshold and require treatment, are different according to the days of life and whether the neonate is healthy or preterm, as summarized in Table 1 While there is a correlation between the risk factors for neonates to become jaundiced and the risks and comorbidities that HIV-exposed neonates face, few studies have compared the incidence of neonatal jaundice between HIVexposed and HIV-non-exposed neonates. The hypothesis of this study was that the incidence of jaundice may be higher in HIV-exposed neonates than in HIV-non-exposed neonates.
Methods

Study population, sample size, and study setting
This prospective cohort study was conducted at the Gogo Chatinkha Nursery (CN) neonatal unit at Queen Elizabeth Central Hospital over a four-week period. The admission criteria for CN includes those neonates who are premature, of low birth weight, or are exibiting any danger signs in a neonate, for example, dyspnoea or poor colour. The study population comprised neonates admitted to CN. Only neonates who met the inclusion criteria were included in the study after consent was obtained from their mothers. The inclusion criteria were that newborn babies had to be free from jaundice and admitted to CN. The following were not eligible for the study: neonates who already had jaundice, neonates with significant congenital anomalies, and neonates of mothers whose HIV statuses were not known. The study participants were recruited using stratified sampling. Two groups of eligible neonates whose mothers were HIV-positive and HIV-negative were identified. A random sample of 69 babies was drawn from each group. The calculated sample size of 138 (69 exposed and 69 nonexposed) babies was generated using Epi info version 3.5, with a confidence level of 90%, power of 80%, exposed to non exposed-ratio of 1:1, risk ratio of 2.31, and an odds ratio of 3. However, we did not reach our sample size, as only 17 HIV-exposed neonates were recruited. 149 neonates were recruited in order to increase the number of HIV-exposed neonates in the study, as not many HIV-exposed neonates were admitted to CN during the data collection period. Data on the sampled babies were collected using self-administered questionnaires, which were provided to the mothers. Data were analysed using Epi Info 3.5 software.
Ethical considerations
Ethical approval was granted by the College of Medicine Research and Ethics Committee (COMREC). Informed written consent was sought from the mothers of the neonates. Before consent was obtained, the mothers were assured of confidentiality. Study subjects were each assigned unique identification numbers.
Data collection
Once the mothers consented, details of the mother and baby were recorded on data collection forms. Babies had wrist bands on which their mothers' names were written. These wristbands were checked daily before taking any measurements from the babies.
Data management
Bilirubin levels were measured using a transcutaneous bilirubinometer, which was placed on the sternum and forehead of each baby, and the highest reading was recorded. Axillary temperatures were also measured using a thermometer. If a study subject's level of bilirubin was above the accepted treatment threshold, the investigators (three of whom were fourth-year medical students at the time of data collection) discussed the case with the doctor on duty for information about the treatment plan for the baby. The babies who developed jaundice were started on phototherapy. The measurements for temperature and bilirubin were taken every day for the duration of stay of the baby in CN. If pyrexia or changes in condition of the study patients was noted by the investigators, this information was immediately relayed to the clinicians responsible for patient care. Babies who developed jaundice, as well as those who did not, were monitored throughout their duration of stay in CN.
Data analysis
Microsoft Excel 2011 and Epi info 3.5 were used to record, store, and analyse the data that were collected.
Results
The total number of admitted neonates from 11 September 2013 to 9 October 2013 was 251. Of the 251 neonates admitted to CN, 149 neonates were recruited into the study. The prevalence of HIV among mothers giving birth at QECH was 13.8%. Sixty-one percent (91/149) of the neonates recruited into the study were males. Ten mothers (6.3%) who gave consent had not been tested for HIV, hence children born to these mothers were excluded from the study. Over 75% of neonates admitted to CN developed clinical jaundice (Table 3) . Over half (64%) of the neonates with clinical jaundice were male, while the remainder (36.0%) were female. Gender was significantly associated with clinical jaundice (p = 0.033). About 80% of neonates had low birth weight. Seventy percent of neonates with normal birth weight (birth weight ≥ 2500g) developed clinical jaundice. However, birth weight was not significantly associated with clinical jaundice (p = 0.140). About half of the HIV-exposed neonates and the majority (81%) of the HIV-non-exposed neonates developed clinical jaundice (Figure 1 ). HIV non-exposure was significantly associated with clinical jaundice (p < 0.001). Over 70% of full-term neonates and about 80% of preterm neonates developed clinical jaundice.
Fifteen of the 17 HIV-exposed neonates were given nevirapine, as the mothers of two HIV-exposed neonates refused nevirapine prophylaxis. About 10% of the neonates developed severe jaundice and were put on phototherapy. Most of the neonates who developed severe jaundice were HIV-non-exposed ( Figure  3 ). About 13% of neonates with low birth weights and 15% of neonates with normal birth weights developed severe jaundice. About 6% of HIV-exposed neonates and 14% of HIV-non-exposed neonates developed severe jaundice. 
Discussion
Our study showed a strong negative association between the incidence of clinical jaundice and HIV exposure. Contrary to our initial hypothesis, the incidence of neonatal jaundice at CN was less in the HIV-exposed than in the HIV-nonexposed group. There was no association between HIV exposure and severe jaundice. Studies have found high rates of prematurity, low birth weight, and very low birth weight in the infants of HIVpositive mothers. 8, 9 Notably, prematurity and low birth weight are risk factors that predispose HIV-exposed neonates to develop jaundice. The incidence of neonatal jaundice at CN was, however, less in the HIV-exposed than in the HIV nonexposed babies, and several explanations could be suggested for the results obtained. First, it could be because of the relatively small sample size of the study. There were fewer HIV-exposed neonates admitted to CN than we initially expected. This could be because most HIV-exposed neonates who were born at QECH did not meet the criteria to be admitted to CN. Consequently, the number of HIV-exposed neonates was small and this affected our statistical analysis. The results cannot be generalised to the population. Additionally, many of the HIV-exposed neonates who were admitted to CN were of low birth weight and premature, did not have other co-morbidities and were discharged within two days after admission. Bilirubin levels generally peaked on days 3 and 4 (Figure 2 ), but since most HIV-exposed neonates stayed at CN for less than 2 days, the results show Table 4 : Association between severe jaundice and demographic characteristics of study participants The peak and fall in bilirubin levels was similar for both clinical and severe jaundice (Figure 4 that they did not develop jaundice. However, these HIVexposed neonates might have developed jaundice after discharge and presented to health centres elsewhere. Furthermore, controlling for confounders using logistic regression, gender and maternal HIV status were negatively and significantly associated with clinical jaundice. This agrees with previous research done elsewhere, which showed that male gender is a known risk factor for pathological jaundice. 13 Birth weight, gestational age, and mode of delivery were not significantly associated with jaundice. A possible hypothesis as to why HIV-exposed neonates were less likely to develop jaundice, at least in the initial days of life, might be related to the Malawi's current PMTCT protocol. The national PMTCT guidelines stipulate that all HIV-seroreactive pregnant and breastfeeding women should be started on an antiretroviral therapy regimen that contains efavirenz (along with tenofovir and lamivudine). The efavirenz may act as a foetal liver enzyme inducer, and this would help in the conjugation of bilirubin, resulting in HIV-exposed neonates having less serum bilirubin levels than their HIV-non-exposed counterparts.
Limitations
The study used a non-invasive technique (transcutaneous bilirubinometer) for measuring the bilirubin levels. These devices are not always accurate, especially if the neonate has been placed under phototherapy. Using the gold standardserum birubin level measurement-would have been more ideal.
The number of neonates who developed jaundice could be higher than that found in this study because most neonates developed jaundice after being discharged from the ward, and this depended on the mothers noticing that their child was looking yellowish. Lastly, The sample size for HIV-exposed infants was not reached, as we recruited only 17 of the calculated 69 neonates. The study period could have been increased, or the study field could have been extended to other health facilities in order to have had a larger sample size. With a larger sample size, our results could have, at least, approached generalisability on a national level.
Conclusions
This short cohort study showed that, in young neonates, jaundice was less common in HIV-exposed babies despite the use of nevirapine. Although this is reassuring, a larger study with longer follow-up is needed.
